Navigation Links
PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
Date:1/16/2013

Seattle Washington (PRWEB) January 16, 2013

Plexera®, LLC, a worldwide provider of label-free surface plasmon resonance imaging (SPRi) technology solutions for functional proteomics, announced today the official launch of its contract research effort based in offices of Plexera LLC located at the Institute for Systems Biology (ISB). Plexera will perform advanced kinetic interaction analysis on either customer provided samples or Plexera provided targets and libraries.

“Through the use of array-formatted label-free, real-time detection and a diverse choice of surface chemistries, customers can avoid the changes to molecular interactions introduced by chemical and biological labeling techniques” says Dr. Zhang, director of Applications at Plexera.

Applications include high-throughput screening, affinity analysis, and specificity determination. Complete service provides custom NanoCapture® chip chemistry selection and preparation, ligand generation and characterization, multiple array production, full kinetic data and analysis, and a full service report. Plexera will take advantage of extensive laboratory facilities at ISB to offer customers a fully integrated service including immunoassay and MS analysis in addition to SPRi studies. The company has completed several studies to date including , small molecule screening, glycoprotein profiling , antibody epitope mapping, and pair antibody screening, and is also aggressively forming collaborative partnerships with leading academic institutions in the US and Asia. Most recently the company shipped and installed a system at RIKIN in Japan to study small molecule/protein binding interactions. The company also announced it has manufactured and shipped its 18th PlexArray® HT system since launched in 2011 and has been awarded its 11th patent surrounding the SPRi technology.

“We are very pleased with the depth of our patent portfolio and the ever increasing inventory of application developments we have made over the last year.” Says Dr. Jinsong Zhu, CEO, Plexera LLC. “As indicated by customer interest the HT application for interaction studies is certainly an emerging commercial technology today.”

ABOUT PLEXERA, LLC.
Plexera LLC (http://www.plexera.com) is a Washington state company providing advanced SPRi-based solutions for functional proteomics. The company has development and manufacturing facilities at its headquarters in Woodinville, WA and has application laboratories in Seattle at the Institute for Systems Biology. The company is exclusively represented for development and marketing in Guangzhou, China by Guangzhou Gaotong Biotechnology Co., Ltd. and PuRui TongLiang Beijing Biotechnology company Ltd. in Beijing. In Japan, the company is exclusively represented by Cell Produce Co., Ltd.
The PlexArray® HT System is a high-throughput, label-free, SPR-based biomolecular interaction detection system for producing high quality information on kinetics, affinities, and specificities among proteins, peptides, small molecules, and genetic materials. The PlexArray HT serves a wide range of industries including pharmaceutical, biomarker R&D, and assay development. A variety of samples can be measured in 15 minutes and thousands of molecule interactions in only 30 minutes. NanoCapture® Biosensor Chips feature high array density (>1,000 spots interrogated simultaneously), variable array spot size (=100 µm), and multiple surface chemistries for protein, nucleic acid, small molecule, or live cell immobilization.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10320468.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Savory, LLC Launches Website and Blog for Water Filtration Systems
2. AkAsha International Launches Children's Book Series
3. NIH launches collaborative effort to find biomarkers for Parkinsons
4. Dr. S. Mark McKenna CEO of ShapeMed (Atlanta, GA) Launches Innovative Fitness App Nationwide
5. U.S. Launches Extensive Alzheimers Studies
6. Dr. Harvey’s Launches "Oracle": a Revolutionary Freeze-Dried, Highly Nutritious and Protein-Rich Line of Complete Foods for Dogs and Cats
7. Marketing Xocolate International Corporation (MXI Corp) Launches “The Whole Story” World Tour To Highlight Xocai Healthy Chocolate Product, Full-Line Up of Guest Speakers
8. LeftBrainRightBrainTest.com Launches New and Informative Test
9. Educational First Steps Launches Four Steps to Excellence 2.0 Program
10. Dr. Vonda Wright, MD. Launches 13-Week "Guide to Thrive" Blog
11. Tiger Schulmann’s MMA Launches New Improved Website and Blog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: